查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1466375

免疫檢測市場：按產品、技術、檢體、適應症和最終用戶 - 2024-2030 年全球預測

Immunoassay Market by Product (Analyzer, Consumables), Technology (Chemiluminescence Immunoassay, Enzyme-linked Immunosorbent Assay, Fluoroimmunoassay), Specimen, Indication, End User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年免疫檢測市場規模為263億美元，預計2024年將達282.9億美元，2030年將達429億美元，複合年成長率為7.24%。

免疫檢測是一種靈敏且特異性的生化技術，用於定量和檢測各種分子，包括蛋白質、荷爾蒙、抗體和其他生物學相關物質。免疫檢測市場的成長是由多種因素推動的，例如慢性病盛行率的增加、個人化醫療需求的增加、免疫檢測在腫瘤診斷中的廣泛使用以及技術進步導致準確性和高通量性能的提高。此外，由於對快速檢測解決方案的需求激增，COVID-19 大流行也對該市場的成長做出了重大貢獻。然而，先進免疫檢測系統的高成本可能會阻礙其在小型實驗室和資源有限的環境中的採用。此外，嚴格的產品核可監管指南可以延長新產品的上市時間。為了克服這些挑戰並維持免疫檢測市場的業務成長，公司正在創建具有成本效益的解決方案，以滿足全球各種醫療保健環境中更廣泛的用戶群，我們正在探索技術創新和研究的可能性，例如專注於。此外，我們也與學術機構和研究中心合作，促進檢測設計的突破性創新，針對現有產品目前無法解決的新型分析物和應用。除此之外，市場參與企業正在開發用於早期疾病檢測的新型生物標記物，從而擴大免疫檢測的臨床應用。

主要市場統計
基準年[2023] 263億美元
預測年份 [2024] 282.9億美元
預測年份 [2030] 429億美元
複合年成長率（%） 7.24%

產品開發用於診斷感染疾病和自體免疫疾病的新型免疫檢測套件

分析儀是免疫檢測的核心，有助於檢測和測量檢體中的目標分析物。這些分析儀用於臨床實驗室、醫院、製藥公司和研究機構，用於篩檢各種生物標記並檢測特定分析物，如荷爾蒙、蛋白質和病原體。因此，對具有快速週轉時間、高通量和易於使用的介面的分析儀的需求不斷成長。為了滿足這些需求，製造商正在引入創新技術，例如基於化學冷光的檢測系統、多重檢測和先進的軟體解決方案，以提高效率並提供準確的結果。

耗材在免疫檢測中發揮至關重要的作用，透過高品質的試劑、套件和其他一次性物品來確保可靠的測試結果。在消耗品中，試劑透過促進抗體和抗原之間的特異性結合相互作用，在進行免疫檢測中發揮重要作用。試劑包括一抗、二抗、酵素標結合物、基材、緩衝液和其他必要的化學物質。這些試劑的性能特徵直接影響測定的可靠性和重現性。免疫檢測套件由一組預先包裝的試劑以及用於執行特定測定的詳細方案組成。易用性、標準化和最佳化性能等優點正在推動世界各地實驗室對即用型套件的需求。孔盤和管子作為各種免疫檢測的支撐結構，透過允許同時分析多個樣品來提供可擴展性和高通量能力。其材料成分在最大限度地減少特異性結契約時保持分析物檢測的最佳條件方面發揮著重要作用。

技術 利用酵素結合免疫吸附測定技術治療食物過敏及藥物濫用

化學冷光免疫檢測(CLIA) 是一種靈敏且特異性的技術，透過化學反應發出的光來測量分析物的濃度。 CLIA 最近因其高通量、快速結果和良好的信噪比而受到歡迎，有利於檢測低豐度生物標記、感染疾病和荷爾蒙水平。酵素連結螢光測定 (ELFA) 使用酵素連結抗體和螢光基材來定量特定分析物。 ELFA 可在相對較小的樣品量中提供具有高靈敏度和特異性的快速分析。該技術可用於多種應用，包括感染疾病診斷、自體免疫疾病檢測和治療藥物監測。酵素結合免疫吸附檢測法(ELISA) 廣泛用於診斷和研究應用，以檢測蛋白質、勝胜肽、荷爾蒙和抗體。 ELISA 具有高靈敏度、特異性和重現性，並且可輕鬆適應微孔盤和以微珠為基礎的形式。免疫檢測是一種使用放射性同位素檢測生物樣本中目標分子的成熟技術。儘管隨著非放射性技術的出現，RIA 的受歡迎程度有所下降，但 RIA 在某些利基應用中仍然具有重要意義，例如測量低水平激素、藥物監測和評估受體結合研究。快速診斷測試是即時檢測設備，可以從血液或尿液等檢體中快速獲得結果，而不需要專門的測試設備或人員。這些測試已成為資源有限環境中感染疾病診斷、懷孕和藥物濫用篩檢的重要工具。

使用非侵入性檢體採集方法進行唾液診斷的出現

免疫檢測檢體的選擇取決於多種因素，例如感興趣的疾病類型、生物標記的可用性、檢體採集的難易程度以及患者的舒適度。血液通常是免疫檢測的檢體，因為它可以全面了解個人的健康狀況。血液通常用於檢測感染疾病、癌症生物標記、荷爾蒙水平、自體免疫疾病等。唾液因其非侵入性採集方法以及易於儲存和運輸普及流行的血液檢體，特別是在檢測荷爾蒙水平、藥物濫用測試、識別口腔病原體和評估整體口腔健康方面有用。尿液也是免疫檢測中常用的檢體，因為它採用非侵入性收集方法，並且能夠檢測多種分析物，例如濫用藥物、懷孕荷爾蒙、腎功能標記和尿道感染指標。

最佳化免疫檢測技術以滿足感染疾病適應症不斷成長的需求

由於全球心血管疾病 (CVD) 的高發生率，循環系統成為免疫檢測市場的關鍵部分。根據世界衛生組織 (WHO) 統計，每年約有 1,790 萬人死於心血管疾病，使其成為全球主要死亡原因。免疫檢測在各種心臟疾病的診斷和監測中發揮重要作用，例如心肌梗塞、心臟衰竭和其他相關疾病。特別是，肌鈣蛋白等生物標記對於評估出現胸痛和其他提示心肌缺血症狀的患者的急性冠狀動脈症候群至關重要。糖尿病、甲狀腺功能障礙和荷爾蒙失衡等內分泌疾病在全球範圍內不斷增加。免疫檢測透過準確定量患者檢體中的荷爾蒙水平來滿足這一需求。感染疾病是免疫檢測市場的另一個重要領域。因為全世界對細菌、病毒和真菌感染的擔憂與日俱增。 COVID-19 大流行進一步凸顯了快速、準確的診斷工具對於識別和監測感染疾病傳播的重要性。免疫檢測對於檢測特定病原體和免疫系統響應感染而產生的抗體非常有價值，從而可以及時採取干涉和遏制措施。在腫瘤學中，免疫檢測對於癌症篩檢、診斷和監測治療效果至關重要。免疫檢測檢測鈣胚抗原（CEA）和前列腺特異性抗原（PSA）等腫瘤生物標記物，幫助臨床醫師對各種惡性進行早期檢測、分期和預後評估，指導針對患者制定治療策略。在整形外科領域，免疫檢測用於監測骨骼代謝標記物，如 i 型前膠原蛋白N 端胜肽(胜肽 ) 和C 端交聯端肽(CTX)，對骨質疏鬆症和其他骨相關疾病的診斷很有幫助。

最終用戶：急診醫學、加護病房和門診診所對免疫檢測的需求不斷增加

由於輸血和血液製品的需要，血庫在免疫檢測市場中扮演重要角色。免疫檢測用於篩檢捐贈者血液樣本中是否有愛滋病毒、B型肝炎、C型肝炎和梅毒等感染疾病。從這些測試中獲得的結果有助於確保血液供應在用於輸血之前的安全。診斷實驗室使用免疫檢測進行常規醫學測試，以檢測生物樣本中存在的各種生物標記。它有助於癌症、糖尿病、心血管疾病和其他慢性疾病的早期診斷。食品和飲料行業需要免疫檢測來檢測食品中的過敏原以及原料和最終產品中的農藥和毒素等污染物。食品和飲料製造商需要檢測極限低的可靠方法，以滿足監管要求並確保消費者安全。醫院是免疫檢測市場的關鍵最終用戶部分之一，因為它們在多個部門廣泛使用這些分析方法進行診斷，包括急診醫學、加護病房和門診診所。免疫檢測有助於快速診斷和監測患者的各種疾病和狀況，使醫療保健專業人員能夠就患者的治療計劃做出明智的決定。製藥公司和委外研發機構(CRO) 在藥物發現、研究和開發以及臨床試驗過程中使用免疫檢測。另一方面，研究和學術實驗室需要免疫檢測來進行涉及訊號傳導途徑和蛋白質-蛋白質相互作用的基礎研究，以及疫苗開發和疾病監測計劃等應用研究計劃。

區域洞察

在美國和加拿大，癌症和心血管疾病等慢性疾病的盛行率不斷上升，推動了對免疫檢測的需求。這些國家醫療保健支出的增加也伴隨著對疾病早期發現的日益關注。實驗室正大力投資酵素結合免疫吸附檢測法（ELISA）和化學冷光檢測法（CLIA）等先進技術。除此之外，最近在該領域申請的專利還包括提高檢測靈敏度和特異性，同時減輕交叉反應問題。在歐盟國家中，由於消費者健康意識的提高，中東和非洲地區的免疫檢測市場正經歷顯著成長。由政府和醫療機構主導的舉措正在增加對診斷服務的公共投資。新興市場的主要參與者正在專注於開發滿足特定區域客戶需求的新產品。印度和中國等亞太地區的新興經濟體面臨著醫療費用上漲、慢性病患病率上升、需要診斷檢測服務、實驗室基礎設施改善以及早期疾病檢測意識增強等問題，這為醫療保健行業創造了巨大的免疫檢測機會。此外，針對新興市場特定疾病模式的產品客製化有助於擴大核心概況。此外，地方政府推出了多項舉措，以促進創新診斷開發的官民合作關係，為學術機構和私人企業提供支援和投資。

FPNV定位矩陣

FPNV定位矩陣對於評估免疫檢測市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對免疫檢測市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.免疫檢測市場的市場規模與預測是多少？

2.在免疫檢測市場的預測期間內，有哪些產品、細分市場、應用和領域需要考慮投資？

3.免疫檢測市場的技術趨勢和法規結構是什麼？

4.免疫檢測市場主要廠商的市場佔有率為何？

5. 進入免疫檢測市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病和感染疾病的增加以及早期診斷的好處
      • 免疫檢測在食品和飲料行業中的使用增加
      • 多重檢測技術在藥物研發的新應用
    • 抑制因素
      • 與免疫檢測相關的交叉反應問題
    • 機會
      • 與免疫檢測相關的自動化儀器和設備數量的技術進步
      • 免疫檢測在環境監測中的巨大潛力
    • 任務
      • 由於樣品品質和試劑性能的變化而導致的測定檢驗問題
  • 市場區隔分析
    • 產品：開發用於診斷感染疾病和自體免疫疾病的新型免疫檢測套件
    • 技術：利用酵素結合免疫吸附測定技術治療食物過敏和藥物濫用
    • 檢體：使用非侵入性採集方法進行唾液診斷的出現
    • 適應症：最佳化免疫檢測技術以整體感染疾病不斷成長的需求
    • 最終用戶：急診醫學、加護病房和門診診所對免疫檢測的需求正在增加
  • 市場趨勢分析
    • 介紹一種由政府資助的新型永續免疫檢測，旨在擴大美洲的免疫檢測
    • 亞太地區感染疾病和自體免疫疾病的流行以及對高效醫療解決方案日益成長的需求
    • 隨著政府對更多採用免疫檢測的支持的增加，醫療保健公司正在增加其在歐洲、中東和非洲地區的業務。
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法規結構分析

第6章免疫檢測市場：依產品

  • 分析儀
  • 消耗品

第7章免疫檢測市場：依技術分類

  • 化學冷光免疫檢測
  • 酵素免疫分析法
  • 螢光免疫分析
  • 免疫檢測
  • 快速診斷測試 (RDT)/側流免疫檢測

第8章免疫檢測市場（按樣本）

  • 血
  • 唾液
  • 尿

第9章按適應症分類的免疫檢測市場

  • 心臟病學
  • 內分泌學
  • 感染疾病
  • 腫瘤學
  • 整形外科

第 10 章免疫檢測市場：依最終使用者分類

  • 血庫
  • 診斷實驗室
  • 食品和飲料公司
  • 醫院
  • 製藥公司和 CRO
  • 研究/學術機構

第11章：美洲免疫檢測市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太免疫免疫檢測市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲的免疫檢測市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Thermo Fisher 斥資 31 億美元收購 Olink，擴大蛋白質體學業務
    • FUJIREBIO和 Sysmex 合作開發獨特的免疫檢測方法
    • 邁瑞同意收購德國 Diasys 診斷系統公司 75% 的股份
    • CVC基金「島津未來創新基金」投資了開發免疫檢測技術的IMMUNOSENS Co., Ltd.。
    • Fapon推出新型化學冷光系統
    • Beckman Coulter 的 DxI 9000免疫檢測分析儀具有改進的分析開發靈敏度，在 2023 年 AACC 北美首次亮相
    • 貝克曼庫爾特 (Beckman Coulter) 和FUJIREBIO合作，增強患者友善血液阿茲海默症檢測的可及性
    • Makati Med 成為菲律賓和東協第一家購買 Atelica VTLi 病患側免疫檢測的醫院
    • QuidelOrtho Sofia 2 SARS 抗原+FIA 獲得 FDA De Novo 批准
    • SGS 在普瓦捷實驗室提供增強型自動化免疫檢測測試
    • 西門子建立免疫檢測儀器研發卓越中心

第15章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-43127F7279BC

[194 Pages Report] The Immunoassay Market size was estimated at USD 26.30 billion in 2023 and expected to reach USD 28.29 billion in 2024, at a CAGR 7.24% to reach USD 42.90 billion by 2030.

An immunoassay is a highly sensitive and specific biochemical technique used to quantify or detect a wide range of molecules, including proteins, hormones, antibodies, and other biologically relevant substances. The growth of the immunoassay market can be attributed to several influencing factors, such as the increasing prevalence of chronic diseases, rising demand for personalized medicine, expanding use of immunoassays in oncology diagnostics, and advancements in technology leading to higher throughput capabilities with improved accuracy. Moreover, the COVID-19 pandemic has also contributed significantly to the growth of this market due to the surge in demand for rapid testing solutions. However, high costs associated with advanced immunoassay systems may hamper their adoption by smaller laboratories or resource-limited settings. Additionally, stringent regulatory guidelines regarding product approvals can prolong the time to market for new products. To overcome these challenges and sustain business growth in the immunoassay market, organizations are exploring potential areas of innovation and research, including focusing on R&D efforts to create cost-effective solutions that cater to a wider user base across different healthcare settings worldwide. Additionally, collaborating with academic institutions and research centers to foster breakthrough innovations in assay design, targeting novel analytes or applications not currently addressed by existing products. Along with these, market participants are developing novel biomarkers for the early detection of diseases, leading to an expansion in clinical applications of immunoassays.

KEY MARKET STATISTICS
Base Year [2023] USD 26.30 billion
Estimated Year [2024] USD 28.29 billion
Forecast Year [2030] USD 42.90 billion
CAGR (%) 7.24%

Product: Development of novel immunoassay kits for diagnostics of infectious and autoimmune diseases

Analyzers are at the core of immunoassays as they facilitate the detection and measurement of target analytes in samples. These analyzers are typically used in clinical laboratories, hospitals, pharmaceutical companies, and research institutions to screen for various biomarkers and detect specific analytes such as hormones, proteins, and pathogens. There has been a growing need for analyzers with rapid turnaround times (TAT), high-throughput capabilities, and user-friendly interfaces. In response to these needs, manufacturers have introduced innovations such as chemiluminescence-based detection systems, multiplexed assays, and advanced software solutions to improve efficiency and provide accurate results.

Consumables play a critical role in immunoassays by ensuring reliable test results through high-quality reagents, kits, and other disposable items. In consumables, reagents play an essential role in performing immunoassays by facilitating specific binding interactions between antibodies and antigens. These include primary and secondary antibodies, enzyme-labeled conjugates, substrates, buffers, and other necessary chemicals. The performance characteristics of these reagents directly affect assay reliability and reproducibility. Immunoassay kits consist of a complete set of pre-packaged reagents, along with detailed protocols for conducting specific assays. Advantages such as ease of use, standardization, and optimized performance have increased demand for ready-to-use kits in laboratories worldwide. Microwell plates and tubes serve as support structures for various immunoassays, offering scalability and high-throughput capabilities by allowing multiple samples to be analyzed simultaneously. Their material composition plays a significant role in minimizing non-specific binding while maintaining optimal conditions for analyte detection.

Technology: Utilization of enzyme-linked immunosorbent assay technology for food allergies and drugs of abuse treatment

The chemiluminescence immunoassay (CLIA) is a highly sensitive and specific technology that measures the concentration of an analyte through the emission of light from a chemical reaction. CLIA has gained popularity recently due to its high throughput, rapid results, and favorable signal-to-noise ratios, which are beneficial in detecting low-abundance biomarkers, infectious diseases, and hormone levels. Enzyme-linked fluorescence assays (ELFA) involve using enzyme-labeled antibodies and fluorescent substrates to quantify specific analytes. ELFA provides a rapid analysis with high sensitivity and specificity while requiring relatively small sample volumes. This technology finds utility in various applications such as infectious disease diagnosis, autoimmune disorders detection, and therapeutic drug monitoring. Enzyme-linked immunosorbent assays (ELISA) are widely used in diagnostics and research applications to detect proteins, peptides, hormones, and antibodies. ELISA offers high sensitivity, specificity, and reproducibility with the convenience of being adaptable to both microplate and bead-based formats. Radioimmunoassay is a well-established technique that uses radioisotopes to detect target molecules in biological samples. Despite its declining popularity due to the emergence of non-radioactive techniques, RIA still holds relevance in specific niche applications such as the measurement of low-concentration hormones, drug monitoring, and assessment of receptor binding studies. Rapid diagnostic tests are point-of-care testing devices offering quick results from a sample such as blood or urine without requiring specialized laboratory equipment or personnel. These tests have become vital tools in diagnosing infectious diseases, pregnancy, and drug abuse screening in resource-limited settings.

Specimen: Emergence of saliva diagnostics due to its non-invasive collection methods

The choice of immunoassay specimen depends on factors such as the type of disease targeted, biomarker availability, ease of sample collection, and patient comfort. Blood is often the preferred specimen type for immunoassays due to its ability to provide comprehensive insights into an individual's health status. It is routinely used to detect infectious diseases, cancer biomarkers, hormone levels, and autoimmune disorders, among other applications. Saliva has emerged as a popular alternative to blood due to its non-invasive collection methods and ease of storage/transportation, which is particularly useful for detecting hormone levels, drug abuse testing, oral pathogens identification, and assessment of overall oral health status. Urine is another widely used specimen type in immunoassays due to its non-invasive collection procedure and ability to detect a wide range of analytes, such as drugs of abuse, pregnancy hormones, kidney function markers, and urinary tract infection indicators.

Indication: Optimization within immunoassay technologies to cater growing need across infectious disease

Cardiology is a major segment in the immunoassay market owing to the high prevalence of cardiovascular diseases (CVDs) worldwide. According to the World Health Organization, cardiovascular diseases account for approximately 17.9 million deaths annually, making it a major cause of mortality globally. Immunoassays play a critical role in diagnosing and monitoring various cardiac conditions such as myocardial infarction, heart failure, and other related disorders. In particular, biomarkers such as troponin are essential for evaluating acute coronary syndrome in patients presenting with chest pain or other symptoms suggestive of myocardial ischemia. Endocrine disorders like diabetes, thyroid dysfunction, and hormonal imbalances are increasingly affecting global populations. Immunoassays cater to this demand by accurately quantifying hormone levels in patients' samples. Infectious Disease represents another significant area within the immunoassay market due to widespread concerns over bacterial, viral, and fungal infections worldwide. The COVID-19 pandemic has further highlighted the importance of rapid and accurate diagnostic tools to identify and monitor the spread of infectious diseases. Immunoassays are valuable in detecting specific pathogens or antibodies produced by the immune system in response to infection, enabling timely intervention and containment measures. In Oncology, immunoassays have become indispensable for cancer screening, diagnosis, and monitoring treatment effectiveness. Immunoassays detect tumor biomarkers such as carcinoembryonic antigen (CEA) or prostate-specific antigen (PSA) that can aid clinicians in early detection, staging, and prognostic evaluation of various malignancies and guiding personalized therapeutic strategies for patients. In the field of orthopedics, immunoassays are used to monitor bone metabolism markers like procollagen type I N-terminal propeptide (PINP) and C-terminal cross-linking telopeptide (CTX), which assist in diagnosing osteoporosis and other bone-related disorders.

End User: Rising demand for immunoassay across emergency care, intensive care units, and outpatient clinics

Blood banks play a critical role in the immunoassay market due to the need for blood transfusions and blood-based products. Immunoassays are employed to screen for infectious diseases such as HIV, Hepatitis B and C, and syphilis in donor blood samples. The results obtained from these tests help ensure the safety of blood supplies before they are used for transfusion purposes. Diagnostic laboratories perform routine medical tests using immunoassays to detect different biomarkers present in biological samples. Across laboratories, assays aid in early diagnostics of diseases such as cancer, diabetes, cardiovascular disorders, and other chronic conditions. The food & beverage industry requires immunoassays for testing allergens in food products and contaminants, including pesticides and toxins in raw materials or finished goods. Food & beverage seek reliable methods with low detection limits to meet regulatory requirements and ensure consumer safety. Hospitals constitute one of the significant end-user segments of the immunoassay market due to their extensive use of these assays for diagnostic purposes across multiple departments, such as emergency care, intensive care units, and outpatient clinics. Immunoassays aid in the rapid diagnosis and monitoring of various diseases and conditions in patients, enabling healthcare professionals to make informed decisions regarding patient treatment plans. Pharmaceutical companies and contract research organizations (CROs) rely on immunoassays for drug discovery, development, and clinical trial phases. Whereas research & academic labs often need specialized immunoassays for basic research studies involving signaling pathways, protein-protein interactions, and applied research projects such as vaccine development and disease surveillance programs.

Regional Insights

In the Americas, the United States and Canada have witnessed a growing demand for immunoassays due to a rising prevalence of chronic diseases such as cancer and cardiovascular disorders. Increasing healthcare spending in these countries has also supplemented increased focus on early detection of diseases; laboratories are investing heavily in advanced technologies such as enzyme-linked immunosorbent assays (ELISA) and chemiluminescence immunoassays (CLIA). Apart from these, recent patents filed in this region encompass improvements in assay sensitivity and specificity while reducing cross-reactivity issues. In EU countries, the Middle East and Africa region has seen significant growth in the immunoassay market due to rising consumer health awareness. Initiatives led by governments and healthcare organizations have bolstered public investment in diagnostic services. Key players in this market focus on developing new products catering to specific regional customer requirements. Emerging countries across the Asia Pacific, such as India and China, present a considerable growth opportunity for immunoassay manufacturers due to increasing healthcare expenditure, rising prevalence of chronic diseases requiring diagnostic testing services, improving laboratory infrastructure, and growing awareness about early disease detection. Furthermore, customizing products to cater to specific disease patterns in emerging markets has helped expand key profiles. Additionally, the regional government has launched several initiatives to promote public-private partnerships in developing innovative diagnostic methods, providing support and investment for academic institutions and private enterprises.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Immunoassay Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Immunoassay Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Immunoassay Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies Inc., Almac Group Limited, ANP Technologies, Inc., Autobio Diagnostics Co., Ltd., Becton, Dickinson, and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, BioLegend, Inc., bioMerieux S.A., Biosurfit SA, Boditech Med Inc., Charles River Laboratories International, Inc., Danaher Corporation, Diasorin S.p.A., Dynex Technologies, Inc., Epitope Diagnostics Inc., F. Hoffmann-La Roche Ltd., Fapon Biotech Inc., Gyros Protein Technologies AB, H.U. Group Holdings Inc., J. Mitra & Co. Pvt. Ltd., Kamiya Biomedical Company, Koninklijke Philips N.V., Merck KGaA, MiCo BioMed, Inc., NanoEntek, Nanomix, Inc., OPKO Health, Inc., PerkinElmer, Inc., Promega Corporation, QIAGEN N.V., Quanterix Corporation, QuidelOrtho Corporation, Randox Laboratories Ltd., Shenzhen Micropoint Biotechnologies Co., Ltd., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens Healthineers AG, Sysmex Corporation, Tecan Trading AG, Thermo Fisher Scientific Inc., Tosoh Corporation, WAK-Chemie Medical GmbH, Zoetis Inc., and Zybio Inc..

Market Segmentation & Coverage

This research report categorizes the Immunoassay Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Analyzer
    • Consumables
      • Assay Kits
      • Microwell Plates & Tubes
      • Reagents
  • Technology
    • Chemiluminescence Immunoassay
    • Enzyme-linked Immunosorbent Assay
    • Fluoroimmunoassay
    • Radioimmunoassay
    • Rapid Diagnostic Tests (RDTs)/Lateral Flow Immunoassay
  • Specimen
    • Blood
    • Saliva
    • Urine
  • Indication
    • Cardiology
    • Endocrinology
    • Infectious Disease
    • Oncology
    • Orthopedics
  • End User
    • Blood Banks
    • Diagnostics Laboratories
    • Food & Beverage Companies
    • Hospitals
    • Pharmaceutical Companies & CROs
    • Research & Academic Laboratories
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Immunoassay Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Immunoassay Market?

3. What are the technology trends and regulatory frameworks in the Immunoassay Market?

4. What is the market share of the leading vendors in the Immunoassay Market?

5. Which modes and strategic moves are suitable for entering the Immunoassay Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising chronic and infectious diseases and benefits of early diagnosis
      • 5.1.1.2. Growing usage of immunoassay in the food & beverage sector
      • 5.1.1.3. Emerging application of multiplex detection immunoassay technique in drug development
    • 5.1.2. Restraints
      • 5.1.2.1. Cross-reactivity issues associated with immunoassay
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in the number of automated instruments and equipment associated with immunoassay
      • 5.1.3.2. High potential of immunoassay in environment monitoring
    • 5.1.4. Challenges
      • 5.1.4.1. Issues with assay validation due to variations in sample quality and reagent performance
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Development of novel immunoassay kits for diagnostics of infectious and autoimmune diseases
    • 5.2.2. Technology: Utilization of enzyme-linked immunosorbent assay technology for food allergies and drugs of abuse treatment
    • 5.2.3. Specimen: Emergence of saliva diagnostics due to its non-invasive collection methods
    • 5.2.4. Indication: Optimization within immunoassay technologies to cater growing need across infectious disease
    • 5.2.5. End User: Rising demand for immunoassay across emergency care, intensive care units, and outpatient clinics
  • 5.3. Market Trend Analysis
    • 5.3.1. Introduction of novel sustainable immunoassays with government funding to scale up of immunoassays in the Americas
    • 5.3.2. Prevalence of infectious and autoimmune diseases, and rising need for efficient healthcare solution in the Asia-Pacific region
    • 5.3.3. Increasing support by government to expand adoption of immunoassay coupled with strong presence of healthcare companies in EMEA region
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework Analysis

6. Immunoassay Market, by Product

  • 6.1. Introduction
  • 6.2. Analyzer
  • 6.3. Consumables

7. Immunoassay Market, by Technology

  • 7.1. Introduction
  • 7.2. Chemiluminescence Immunoassay
  • 7.3. Enzyme-linked Immunosorbent Assay
  • 7.4. Fluoroimmunoassay
  • 7.5. Radioimmunoassay
  • 7.6. Rapid Diagnostic Tests (RDTs)/Lateral Flow Immunoassay

8. Immunoassay Market, by Specimen

  • 8.1. Introduction
  • 8.2. Blood
  • 8.3. Saliva
  • 8.4. Urine

9. Immunoassay Market, by Indication

  • 9.1. Introduction
  • 9.2. Cardiology
  • 9.3. Endocrinology
  • 9.4. Infectious Disease
  • 9.5. Oncology
  • 9.6. Orthopedics

10. Immunoassay Market, by End User

  • 10.1. Introduction
  • 10.2. Blood Banks
  • 10.3. Diagnostics Laboratories
  • 10.4. Food & Beverage Companies
  • 10.5. Hospitals
  • 10.6. Pharmaceutical Companies & CROs
  • 10.7. Research & Academic Laboratories

11. Americas Immunoassay Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Immunoassay Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Immunoassay Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Thermo Fisher to Acquire Olink for USD 3.1 billion, Expanding Proteomics Presence
    • 14.3.2. Fujirebio and Sysmex to Collaborate On Development of Unique Immunoassays
    • 14.3.3. Mindray Has Agreed to Acquire 75% Stake in Germany-Based DiaSys Diagnostic Systems GmbH
    • 14.3.4. CVC Fund "Shimadzu Future Innovation Fund" has Invested in IMMUNOSENS Co., Ltd., Developing Immunoassay Technology.
    • 14.3.5. Fapon Rolls Out New Chemiluminescence Immunoassay System
    • 14.3.6. Beckman Coulter's DxI 9000 Immunoassay Analyzer with Increased Assay Development Sensitivity Makes First North American Appearance at 2023 AACC
    • 14.3.7. Beckman Coulter and Fujirebio Partner to Bolster Access to Patient-friendly, Blood-based Alzheimer's Disease Test
    • 14.3.8. MakatiMed First PH and ASEAN Hospital to Acquire Atellica VTLi Patient-Side Immunoassay Analyzer
    • 14.3.9. QuidelOrtho Receives De Novo FDA Authorization for Sofia 2 SARS Antigen+ FIA
    • 14.3.10. SGS Offers Enhanced Automated Immunoassay Testing at Poitiers Laboratory
    • 14.3.11. Siemens launches Centre of Excellence for Immunoassay Instrument R&D

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. IMMUNOASSAY MARKET RESEARCH PROCESS
  • FIGURE 2. IMMUNOASSAY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL IMMUNOASSAY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. IMMUNOASSAY MARKET DYNAMICS
  • FIGURE 7. GLOBAL IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL IMMUNOASSAY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL IMMUNOASSAY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL IMMUNOASSAY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL IMMUNOASSAY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES IMMUNOASSAY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES IMMUNOASSAY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. IMMUNOASSAY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. IMMUNOASSAY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. IMMUNOASSAY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL IMMUNOASSAY MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNOASSAY MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNOASSAY MARKET SIZE, BY ANALYZER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNOASSAY MARKET SIZE, BY ANALYZER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNOASSAY MARKET SIZE, BY ASSAY KITS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNOASSAY MARKET SIZE, BY ASSAY KITS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNOASSAY MARKET SIZE, BY MICROWELL PLATES & TUBES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNOASSAY MARKET SIZE, BY MICROWELL PLATES & TUBES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNOASSAY MARKET SIZE, BY REAGENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNOASSAY MARKET SIZE, BY REAGENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL IMMUNOASSAY MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL IMMUNOASSAY MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL IMMUNOASSAY MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL IMMUNOASSAY MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL IMMUNOASSAY MARKET SIZE, BY FLUOROIMMUNOASSAY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL IMMUNOASSAY MARKET SIZE, BY FLUOROIMMUNOASSAY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL IMMUNOASSAY MARKET SIZE, BY RADIOIMMUNOASSAY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL IMMUNOASSAY MARKET SIZE, BY RADIOIMMUNOASSAY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL IMMUNOASSAY MARKET SIZE, BY RAPID DIAGNOSTIC TESTS (RDTS)/LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL IMMUNOASSAY MARKET SIZE, BY RAPID DIAGNOSTIC TESTS (RDTS)/LATERAL FLOW IMMUNOASSAY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL IMMUNOASSAY MARKET SIZE, BY BLOOD, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL IMMUNOASSAY MARKET SIZE, BY BLOOD, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL IMMUNOASSAY MARKET SIZE, BY SALIVA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL IMMUNOASSAY MARKET SIZE, BY SALIVA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL IMMUNOASSAY MARKET SIZE, BY URINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL IMMUNOASSAY MARKET SIZE, BY URINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL IMMUNOASSAY MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL IMMUNOASSAY MARKET SIZE, BY CARDIOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL IMMUNOASSAY MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL IMMUNOASSAY MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL IMMUNOASSAY MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL IMMUNOASSAY MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL IMMUNOASSAY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL IMMUNOASSAY MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL IMMUNOASSAY MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL IMMUNOASSAY MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL IMMUNOASSAY MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL IMMUNOASSAY MARKET SIZE, BY BLOOD BANKS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL IMMUNOASSAY MARKET SIZE, BY DIAGNOSTICS LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL IMMUNOASSAY MARKET SIZE, BY DIAGNOSTICS LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL IMMUNOASSAY MARKET SIZE, BY FOOD & BEVERAGE COMPANIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL IMMUNOASSAY MARKET SIZE, BY FOOD & BEVERAGE COMPANIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL IMMUNOASSAY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL IMMUNOASSAY MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL IMMUNOASSAY MARKET SIZE, BY PHARMACEUTICAL COMPANIES & CROS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL IMMUNOASSAY MARKET SIZE, BY PHARMACEUTICAL COMPANIES & CROS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. GLOBAL IMMUNOASSAY MARKET SIZE, BY RESEARCH & ACADEMIC LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 66. GLOBAL IMMUNOASSAY MARKET SIZE, BY RESEARCH & ACADEMIC LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 73. AMERICAS IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 74. AMERICAS IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 75. AMERICAS IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 76. AMERICAS IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 77. AMERICAS IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 78. AMERICAS IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 79. AMERICAS IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 80. AMERICAS IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 81. ARGENTINA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 82. ARGENTINA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 83. ARGENTINA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 84. ARGENTINA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 85. ARGENTINA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 86. ARGENTINA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 87. ARGENTINA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 88. ARGENTINA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 89. ARGENTINA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 90. ARGENTINA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 91. ARGENTINA IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 92. ARGENTINA IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 93. BRAZIL IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 94. BRAZIL IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 95. BRAZIL IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 96. BRAZIL IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 97. BRAZIL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 98. BRAZIL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 99. BRAZIL IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 100. BRAZIL IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 101. BRAZIL IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 102. BRAZIL IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 103. BRAZIL IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 104. BRAZIL IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 105. CANADA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 106. CANADA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 107. CANADA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 108. CANADA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 109. CANADA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 110. CANADA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 111. CANADA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 112. CANADA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 113. CANADA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 114. CANADA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 115. CANADA IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 116. CANADA IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 117. MEXICO IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 118. MEXICO IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 119. MEXICO IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 120. MEXICO IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 121. MEXICO IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 122. MEXICO IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 123. MEXICO IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 124. MEXICO IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 125. MEXICO IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 126. MEXICO IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 127. MEXICO IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 128. MEXICO IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 129. UNITED STATES IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 130. UNITED STATES IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 131. UNITED STATES IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 132. UNITED STATES IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 133. UNITED STATES IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 134. UNITED STATES IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 135. UNITED STATES IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 136. UNITED STATES IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 137. UNITED STATES IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 138. UNITED STATES IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 139. UNITED STATES IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 140. UNITED STATES IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 141. UNITED STATES IMMUNOASSAY MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 142. UNITED STATES IMMUNOASSAY MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 157. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 158. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 159. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 160. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 161. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 162. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 163. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 164. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 165. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 166. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 167. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 168. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 169. CHINA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 170. CHINA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 171. CHINA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 172. CHINA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 173. CHINA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 174. CHINA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 175. CHINA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 176. CHINA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 177. CHINA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 178. CHINA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 179. CHINA IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 180. CHINA IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 181. INDIA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 182. INDIA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 183. INDIA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 184. INDIA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 185. INDIA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 186. INDIA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 187. INDIA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 188. INDIA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 189. INDIA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 190. INDIA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 191. INDIA IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 192. INDIA IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 193. INDONESIA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 194. INDONESIA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 195. INDONESIA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 196. INDONESIA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 197. INDONESIA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 198. INDONESIA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 199. INDONESIA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 200. INDONESIA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 201. INDONESIA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 202. INDONESIA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 203. INDONESIA IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 204. INDONESIA IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 205. JAPAN IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 206. JAPAN IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 207. JAPAN IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 208. JAPAN IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 209. JAPAN IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 210. JAPAN IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 211. JAPAN IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 212. JAPAN IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 213. JAPAN IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 214. JAPAN IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 215. JAPAN IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 216. JAPAN IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 217. MALAYSIA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 218. MALAYSIA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 219. MALAYSIA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 220. MALAYSIA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 221. MALAYSIA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 222. MALAYSIA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 223. MALAYSIA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 224. MALAYSIA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 225. MALAYSIA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 226. MALAYSIA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 227. MALAYSIA IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 228. MALAYSIA IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 229. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 230. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 231. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 232. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 233. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 234. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 235. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 236. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 237. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 238. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 239. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 240. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 241. SINGAPORE IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 242. SINGAPORE IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 243. SINGAPORE IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 244. SINGAPORE IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 245. SINGAPORE IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 246. SINGAPORE IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 247. SINGAPORE IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 248. SINGAPORE IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 249. SINGAPORE IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 250. SINGAPORE IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 251. SINGAPORE IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 252. SINGAPORE IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 253. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 254. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 255. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 256. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 257. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 258. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 259. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 260. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 261. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 262. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 263. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 264. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 265. TAIWAN IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 266. TAIWAN IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 267. TAIWAN IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 268. TAIWAN IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 269. TAIWAN IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 270. TAIWAN IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 271. TAIWAN IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 272. TAIWAN IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 273. TAIWAN IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 274. TAIWAN IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 275. TAIWAN IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 276. TAIWAN IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 277. THAILAND IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 278. THAILAND IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 279. THAILAND IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 280. THAILAND IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 281. THAILAND IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 282. THAILAND IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 283. THAILAND IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 284. THAILAND IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 285. THAILAND IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 286. THAILAND IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 287. THAILAND IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 288. THAILAND IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 289. VIETNAM IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 290. VIETNAM IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 291. VIETNAM IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 292. VIETNAM IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 293. VIETNAM IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 294. VIETNAM IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 295. VIETNAM IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 296. VIETNAM IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 297. VIETNAM IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 298. VIETNAM IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 299. VIETNAM IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 300. VIETNAM IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 313. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 314. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 315. DENMARK IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 316. DENMARK IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 317. DENMARK IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 318. DENMARK IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 319. DENMARK IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 320. DENMARK IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 321. DENMARK IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 322. DENMARK IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 323. DENMARK IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 324. DENMARK IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 325. DENMARK IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 326. DENMARK IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 327. EGYPT IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 328. EGYPT IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 329. EGYPT IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 330. EGYPT IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 331. EGYPT IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 332. EGYPT IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 333. EGYPT IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 334. EGYPT IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 335. EGYPT IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 336. EGYPT IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 337. EGYPT IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 338. EGYPT IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 339. FINLAND IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 340. FINLAND IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 341. FINLAND IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 342. FINLAND IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 343. FINLAND IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 344. FINLAND IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 345. FINLAND IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 346. FINLAND IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 347. FINLAND IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 348. FINLAND IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 349. FINLAND IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 350. FINLAND IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 351. FRANCE IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 352. FRANCE IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 353. FRANCE IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 354. FRANCE IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 355. FRANCE IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 356. FRANCE IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 357. FRANCE IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 358. FRANCE IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 359. FRANCE IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 360. FRANCE IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 361. FRANCE IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 362. FRANCE IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 363. GERMANY IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 364. GERMANY IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 365. GERMANY IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 366. GERMANY IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 367. GERMANY IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 368. GERMANY IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 369. GERMANY IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 370. GERMANY IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 371. GERMANY IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 372. GERMANY IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 373. GERMANY IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 374. GERMANY IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 375. ISRAEL IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 376. ISRAEL IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 377. ISRAEL IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 378. ISRAEL IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 379. ISRAEL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 380. ISRAEL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 381. ISRAEL IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 382. ISRAEL IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 383. ISRAEL IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 384. ISRAEL IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 385. ISRAEL IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 386. ISRAEL IMMUNOASSAY